| Master Investor Magazine
|
AIM-listed healthcare advisory firm Cello Health (LON:CLL) saw its share price fall by 6.31% to 138.20p (as of 13:20 GMT) as it said that the Signal division had been a drag on otherwise strong trading. Management said that the signal arm had performed particularly badly in the fourth quarter but assigned some of this to the impact of the UK general election campaign.
The company said that it would continue to use an acquisitive growth based strategy going forward in to 2019 while looking to split off and dispose of unprofitable business units.